The earnings call presented a positive outlook for Skye Bioscience, with significant progress in the clinical development of nimacimab, strong financial positioning, and strategic team expansion. However, increased R&D expenses and a higher net loss were noted as challenges. Overall, the positive developments and strategic plans outweigh the financial concerns and operational challenges.

Company Guidance -

Q3 2025

During Skye Bioscience's second quarter 2025 financial results and business update call, the company provided detailed guidance on several key metrics and upcoming milestones. The Phase IIa CBeyond study for their peripheral CB1 inhibitor, nimacimab, is advancing ahead of schedule and on budget, with the 26-week visit for the last patient projected to occur soon. The 26-week extension study is underway, with approximately 50% of eligible patients from the original study expected to participate. The company remains on track to deliver top-line results by late Q3 or early Q4 2025. Financially, Skye ended the quarter with $48.6 million in cash and equivalents, maintaining a cash flow guidance to fund operations through at least Q1 2027. Research and development expenses increased to $14.3 million, primarily due to contract manufacturing and clinical trial costs, while general and administrative expenses slightly decreased to $3.9 million. The net loss for the quarter totaled $17.6 million. Skye is preparing for a busy next 90 days, with a KOL event on September 4, a presentation at EASD on September 19, and multiple investor conferences in the fall. The company aims to finalize the Phase IIb protocol and advance CMC activities following the top-line data readout.

Advanced Clinical Progress of Nimacimab

The Phase IIa CBeyond study is advancing as planned, on budget, and ahead of schedule. Enrollment was completed in February, with the 26-week visit for the last patient projected to occur soon. The study has been reviewed four times by the Data Safety Monitoring Committee with no recommendations for changes.

Nimacimab's Potential in Obesity Treatment

Nimacimab demonstrated a 44% vehicle-adjusted weight loss in combination with a suboptimal dose of tirzepatide, outperforming either agent alone. It shows potential as a maintenance therapy to sustain weight loss with better tolerability.

Strong Financial Position

Skye Bioscience ended the second quarter with cash and cash equivalents totaling $48.6 million, which is projected to fund operations through at least Q1 2027.

Positive Preclinical Findings

Nimacimab demonstrated superior durability of weight loss in preclinical studies compared to incretin therapy, maintaining post-treatment weight for approximately 20 days.

Strategic Team Expansion

The company expanded its team to 20 employees, making key hires in regulatory affairs, quality, clinical operations, and CMC to support advancing development activities.

Skye Bioscience (SKYE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SKYE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.30 / -	-0.1	―	―	―
Aug 07, 2025	2025 (Q2)	-0.32 / -0.44	-0.2	-120.00% (-0.24)
May 08, 2025	2025 (Q1)	-0.29 / -0.28	-0.18	-55.56% (-0.10)	―
Mar 20, 2025	2024 (Q4)	-0.28 / -0.24	-0.36	33.33% (+0.12)	―
Nov 07, 2024	2024 (Q3)	-0.25 / -0.10	-3.17	96.85% (+3.07)	―
Aug 09, 2024	2024 (Q2)	-0.20 / -0.20	-0.8	75.00% (+0.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SKYE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$3.55	$3.52	-0.85%
May 08, 2025	$1.79	$1.81	+1.12%
Mar 20, 2025	$1.89	$2.25	+19.05%
Nov 07, 2024	$5.44	$5.71	+4.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Skye Bioscience, Inc. (SKYE) report earnings?

Skye Bioscience, Inc. (SKYE) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Skye Bioscience, Inc. (SKYE) earnings time?

Skye Bioscience, Inc. (SKYE) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SKYE EPS forecast?

SKYE EPS forecast for the fiscal quarter 2025 (Q3) is -0.3.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing